메뉴 건너뛰기




Volumn 32, Issue 1, 2008, Pages 249-255

Ciglitazone, an agonist of peroxisome proliferator-activated receptor γ, exerts potentiated cytostatic/cytotoxic effects against tumor cells when combined with lovastatin

Author keywords

3 hydroxy 3 methylglutaryl coenzyme A; Peroxisome proliferator activated receptor ; Statins; Thiazolidinediones

Indexed keywords

CIGLITAZONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST;

EID: 38749139835     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo.32.1.249     Document Type: Article
Times cited : (9)

References (44)
  • 1
    • 4344568552 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators
    • Theocharis S, Margeli A, Vielh P and Kouraklis G: Peroxisome proliferator-activated receptor-gamma ligands as cell-cycle modulators. Cancer Treat Rev 30: 545-554, 2004.
    • (2004) Cancer Treat Rev , vol.30 , pp. 545-554
    • Theocharis, S.1    Margeli, A.2    Vielh, P.3    Kouraklis, G.4
  • 2
    • 34249948005 scopus 로고    scopus 로고
    • Present concepts and future outlook: Function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer
    • Sertzing PS, Seifert M, Tilgen W and Reichrath J: Present concepts and future outlook: function of peroxisome proliferator-activated receptors (PPARs) for pathogenesis, progression, and therapy of cancer. J Cell Physiol 212: 1-12, 2007.
    • (2007) J Cell Physiol , vol.212 , pp. 1-12
    • Sertzing, P.S.1    Seifert, M.2    Tilgen, W.3    Reichrath, J.4
  • 3
    • 33644954823 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor gamma in malignant diseases
    • Wang T, Xu J, Yu X, Yang R and Han ZC: Peroxisome proliferator-activated receptor gamma in malignant diseases. Crit Rev Oncol Hematol 58: 1-14, 2006.
    • (2006) Crit Rev Oncol Hematol , vol.58 , pp. 1-14
    • Wang, T.1    Xu, J.2    Yu, X.3    Yang, R.4    Han, Z.C.5
  • 4
    • 0037235020 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptor gamma and cancers
    • Koeffler HP: Peroxisome proliferator-activated receptor gamma and cancers. Clin Cancer Res 9: 1-9, 2003.
    • (2003) Clin Cancer Res , vol.9 , pp. 1-9
    • Koeffler, H.P.1
  • 5
    • 3042815666 scopus 로고    scopus 로고
    • Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists
    • Grommes C, Landreth GE and Heneka MT: Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists. Lancet Oncol 5: 419-429, 2004.
    • (2004) Lancet Oncol , vol.5 , pp. 419-429
    • Grommes, C.1    Landreth, G.E.2    Heneka, M.T.3
  • 6
    • 0034540805 scopus 로고    scopus 로고
    • PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells
    • Elnemr A, Ohta T, Iwata K, et al: PPARgamma ligand (thiazolidinedione) induces growth arrest and differentiation markers of human pancreatic cancer cells. Int J Oncol 17: 1157-1164, 2000.
    • (2000) Int J Oncol , vol.17 , pp. 1157-1164
    • Elnemr, A.1    Ohta, T.2    Iwata, K.3
  • 7
    • 25444511570 scopus 로고    scopus 로고
    • The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines
    • Radhakrishnan SK and Gartel AL: The PPAR-gamma agonist pioglitazone post-transcriptionally induces p21 in PC3 prostate cancer but not in other cell lines. Cell Cycle 4: 582-584, 2005.
    • (2005) Cell Cycle , vol.4 , pp. 582-584
    • Radhakrishnan, S.K.1    Gartel, A.L.2
  • 8
    • 0034306992 scopus 로고    scopus 로고
    • Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells
    • Motomura W, Okumura T, Takahashi N, Obara T and Kohgo Y: Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res 60: 5558-5564, 2000.
    • (2000) Cancer Res , vol.60 , pp. 5558-5564
    • Motomura, W.1    Okumura, T.2    Takahashi, N.3    Obara, T.4    Kohgo, Y.5
  • 9
    • 0032555196 scopus 로고    scopus 로고
    • Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
    • Elstner E, Muller C, Koshizuka K, et al: Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA 95: 8806-8811, 1998.
    • (1998) Proc Natl Acad Sci USA , vol.95 , pp. 8806-8811
    • Elstner, E.1    Muller, C.2    Koshizuka, K.3
  • 10
    • 0034235142 scopus 로고    scopus 로고
    • Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis
    • Chattopadhyay N, Singh DP, Heese O, et al: Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. J Neurosci Res 61: 67-74, 2000.
    • (2000) J Neurosci Res , vol.61 , pp. 67-74
    • Chattopadhyay, N.1    Singh, D.P.2    Heese, O.3
  • 11
    • 33749833663 scopus 로고    scopus 로고
    • Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells
    • Vignati S, Albertini V, Rinaldi A, et al: Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. Neoplasia 8: 851-861, 2006.
    • (2006) Neoplasia , vol.8 , pp. 851-861
    • Vignati, S.1    Albertini, V.2    Rinaldi, A.3
  • 12
    • 20344365809 scopus 로고    scopus 로고
    • Therapy insight: Potential of statins for cancer chemoprevention and therapy
    • Katz MS: Therapy insight: Potential of statins for cancer chemoprevention and therapy. Nat Clin Pract Oncol 2: 82-89, 2005.
    • (2005) Nat Clin Pract Oncol , vol.2 , pp. 82-89
    • Katz, M.S.1
  • 13
    • 2542458153 scopus 로고    scopus 로고
    • Potential antitumor effects of statins (Review)
    • Jakobisiak M and Golab J: Potential antitumor effects of statins (Review). Int J Oncol 23: 1055-1069, 2003.
    • (2003) Int J Oncol , vol.23 , pp. 1055-1069
    • Jakobisiak, M.1    Golab, J.2
  • 14
    • 30644478973 scopus 로고    scopus 로고
    • HMG-CoA reductase inhibitors (statins) as anticancer drugs (Review)
    • Fritz G: HMG-CoA reductase inhibitors (statins) as anticancer drugs (Review). Int J Oncol 27: 1401-1409, 2005.
    • (2005) Int J Oncol , vol.27 , pp. 1401-1409
    • Fritz, G.1
  • 15
    • 19444364509 scopus 로고    scopus 로고
    • Statins and the risk of colorectal cancer
    • Poynter JN, Gruber SB, Higgins PD, et al: Statins and the risk of colorectal cancer. N Engl J Med 352: 2184-2192, 2005.
    • (2005) N Engl J Med , vol.352 , pp. 2184-2192
    • Poynter, J.N.1    Gruber, S.B.2    Higgins, P.D.3
  • 16
    • 34248580619 scopus 로고    scopus 로고
    • Statins reduce the risk of lung cancer in humans: A large case-control study of US veterans
    • Khurana V, Bejjanki HR, Caldito G and Owens MW: Statins reduce the risk of lung cancer in humans: a large case-control study of US veterans. Chest 131: 1282-1288, 2007.
    • (2007) Chest , vol.131 , pp. 1282-1288
    • Khurana, V.1    Bejjanki, H.R.2    Caldito, G.3    Owens, M.W.4
  • 17
    • 33644846806 scopus 로고    scopus 로고
    • Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies
    • Bonovas S, Filioussi K, Tsavaris N and Sitaras NM: Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23: 8606-8612, 2005.
    • (2005) J Clin Oncol , vol.23 , pp. 8606-8612
    • Bonovas, S.1    Filioussi, K.2    Tsavaris, N.3    Sitaras, N.M.4
  • 18
    • 33846604584 scopus 로고    scopus 로고
    • Statins and risk of cancer: A systematic review and metaanalysis
    • Browning DR and Martin RM: Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 120: 833-843, 2007.
    • (2007) Int J Cancer , vol.120 , pp. 833-843
    • Browning, D.R.1    Martin, R.M.2
  • 21
    • 17744394863 scopus 로고    scopus 로고
    • Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial
    • Kawata S, Yamasaki E, Nagase T, et al: Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer 84: 886-891, 2001.
    • (2001) Br J Cancer , vol.84 , pp. 886-891
    • Kawata, S.1    Yamasaki, E.2    Nagase, T.3
  • 22
    • 0030010318 scopus 로고    scopus 로고
    • Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer
    • Thibault A, Samid D, Tompkins AC, et al: Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. Clin Cancer Res 2: 483-491, 1996.
    • (1996) Clin Cancer Res , vol.2 , pp. 483-491
    • Thibault, A.1    Samid, D.2    Tompkins, A.C.3
  • 23
    • 0032005580 scopus 로고    scopus 로고
    • Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice
    • Feleszko W, Zagozdzon R, Golab J and Jakobisiak M: Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer 34: 406-411, 1998.
    • (1998) Eur J Cancer , vol.34 , pp. 406-411
    • Feleszko, W.1    Zagozdzon, R.2    Golab, J.3    Jakobisiak, M.4
  • 24
    • 34447282251 scopus 로고    scopus 로고
    • Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo
    • Issat T, Nowis D, Legat M, et al: Potentiated antitumor effects of the combination treatment with statins and pamidronate in vitro and in vivo. Int J Oncol 30: 1413-1425, 2007.
    • (2007) Int J Oncol , vol.30 , pp. 1413-1425
    • Issat, T.1    Nowis, D.2    Legat, M.3
  • 25
    • 33745074201 scopus 로고    scopus 로고
    • Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity
    • Nowis D, Legat M, Grzela T, et al: Heme oxygenase-1 protects tumor cells against photodynamic therapy-mediated cytotoxicity. Oncogene 25: 3365-3374, 2006.
    • (2006) Oncogene , vol.25 , pp. 3365-3374
    • Nowis, D.1    Legat, M.2    Grzela, T.3
  • 26
    • 0021118703 scopus 로고
    • Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors
    • Chou TC and Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984.
    • (1984) Adv Enzyme Regul , vol.22 , pp. 27-55
    • Chou, T.C.1    Talalay, P.2
  • 27
    • 30444453243 scopus 로고    scopus 로고
    • Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone
    • Yao CJ, Lai GM, Chan CF, Cheng AL, Yang YY and Chuang SE: Dramatic synergistic anticancer effect of clinically achievable doses of lovastatin and troglitazone. Int J Cancer 118: 773-779, 2006.
    • (2006) Int J Cancer , vol.118 , pp. 773-779
    • Yao, C.J.1    Lai, G.M.2    Chan, C.F.3    Cheng, A.L.4    Yang, Y.Y.5    Chuang, S.E.6
  • 28
    • 0345687980 scopus 로고    scopus 로고
    • Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells
    • Motomura W, Takahashi N, Nagamine M, et al: Growth arrest by troglitazone is mediated by p27Kip1 accumulation, which results from dual inhibition of proteasome activity and Skp2 expression in human hepatocellular carcinoma cells. Int J Cancer 108: 41-46, 2004.
    • (2004) Int J Cancer , vol.108 , pp. 41-46
    • Motomura, W.1    Takahashi, N.2    Nagamine, M.3
  • 29
    • 0035035402 scopus 로고    scopus 로고
    • Involvement of p21(WAF1/ Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines
    • Koga H, Sakisaka S, Harada M, et al: Involvement of p21(WAF1/ Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines. Hepatology 33: 1087-1097, 2001.
    • (2001) Hepatology , vol.33 , pp. 1087-1097
    • Koga, H.1    Sakisaka, S.2    Harada, M.3
  • 30
    • 0034805978 scopus 로고    scopus 로고
    • Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators
    • Yin F, Wakino S, Liu Z, et al: Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators. Biochem Biophys Res Commun 286: 916-922, 2001.
    • (2001) Biochem Biophys Res Commun , vol.286 , pp. 916-922
    • Yin, F.1    Wakino, S.2    Liu, Z.3
  • 31
    • 0036606010 scopus 로고    scopus 로고
    • Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells
    • Shao J, Sheng H and DuBois RN: Peroxisome proliferator-activated receptors modulate K-Ras-mediated transformation of intestinal epithelial cells. Cancer Res 62: 3282-3288, 2002.
    • (2002) Cancer Res , vol.62 , pp. 3282-3288
    • Shao, J.1    Sheng, H.2    DuBois, R.N.3
  • 32
    • 0035873953 scopus 로고    scopus 로고
    • Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN
    • Patel L, Pass I, Coxon P, Downes CP, Smith SA and Macphee CH: Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 11: 764-768, 2001,
    • (2001) Curr Biol , vol.11 , pp. 764-768
    • Patel, L.1    Pass, I.2    Coxon, P.3    Downes, C.P.4    Smith, S.A.5    Macphee, C.H.6
  • 33
    • 33144483998 scopus 로고    scopus 로고
    • PPAR-gamma agonist increases gefitinib's antitumor activity through PTEN expression
    • Lee SY, Hur GY, Jung KH, et al: PPAR-gamma agonist increases gefitinib's antitumor activity through PTEN expression. Lung Cancer 51: 297-301, 2006.
    • (2006) Lung Cancer , vol.51 , pp. 297-301
    • Lee, S.Y.1    Hur, G.Y.2    Jung, K.H.3
  • 34
    • 0037138434 scopus 로고    scopus 로고
    • Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice
    • Giermasz A, Makowski M, Kozlowska E, et al: Potentiating antitumor effects of a combination therapy with lovastatin and butyrate in the Lewis lung carcinoma model in mice. Int J Cancer 97: 746-750, 2002.
    • (2002) Int J Cancer , vol.97 , pp. 746-750
    • Giermasz, A.1    Makowski, M.2    Kozlowska, E.3
  • 35
    • 0033618378 scopus 로고    scopus 로고
    • 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1)
    • Laufs U, Marra D, Node K and Liao JK: 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem 274: 21926-21931, 1999.
    • (1999) J Biol Chem , vol.274 , pp. 21926-21931
    • Laufs, U.1    Marra, D.2    Node, K.3    Liao, J.K.4
  • 36
    • 0038662665 scopus 로고    scopus 로고
    • Inhibition of cdk2 activating phosphorylation by mevastatin
    • Ukomadu C and Dutta A: Inhibition of cdk2 activating phosphorylation by mevastatin. J Biol Chem 278: 4840-4846, 2003.
    • (2003) J Biol Chem , vol.278 , pp. 4840-4846
    • Ukomadu, C.1    Dutta, A.2
  • 37
    • 34347369084 scopus 로고    scopus 로고
    • Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets
    • Konstantinopoulos PA, Karamouzis MV and Papavassiliou AG: Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets. Nat Rev Drug Discov 6: 541-555, 2007.
    • (2007) Nat Rev Drug Discov , vol.6 , pp. 541-555
    • Konstantinopoulos, P.A.1    Karamouzis, M.V.2    Papavassiliou, A.G.3
  • 38
    • 0036053466 scopus 로고    scopus 로고
    • Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells
    • Takeuchi S, Okumura T, Motomura W, Nagamine M, Takahashi N and Kohgo Y: Troglitazone induces G1 arrest by p27(Kip1) induction that is mediated by inhibition of proteasome in human gastric cancer cells. Jpn J Cancer Res 93: 774-782, 2002.
    • (2002) Jpn J Cancer Res , vol.93 , pp. 774-782
    • Takeuchi, S.1    Okumura, T.2    Motomura, W.3    Nagamine, M.4    Takahashi, N.5    Kohgo, Y.6
  • 39
    • 0033739334 scopus 로고    scopus 로고
    • Lovastatin and simvastatin are modulators of the proteasome
    • Wojcik C, Bury M, Stoklosa T, et al: Lovastatin and simvastatin are modulators of the proteasome. Int J Biochem Cell Biol 32: 957-965, 2000.
    • (2000) Int J Biochem Cell Biol , vol.32 , pp. 957-965
    • Wojcik, C.1    Bury, M.2    Stoklosa, T.3
  • 40
    • 0036158675 scopus 로고    scopus 로고
    • 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis
    • Kusama T, Mukai M, Iwasaki T, et al: 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology 122: 308-317, 2002.
    • (2002) Gastroenterology , vol.122 , pp. 308-317
    • Kusama, T.1    Mukai, M.2    Iwasaki, T.3
  • 41
    • 0036771776 scopus 로고    scopus 로고
    • PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis
    • Panigrahy D, Singer S, Shen LQ, et al: PPARgamma ligands inhibit primary tumor growth and metastasis by inhibiting angiogenesis. J Clin Invest 110: 923-932, 2002.
    • (2002) J Clin Invest , vol.110 , pp. 923-932
    • Panigrahy, D.1    Singer, S.2    Shen, L.Q.3
  • 42
    • 0028925366 scopus 로고
    • Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice
    • Feleszko W, Lasek W, Golab J and Jakobisiak M: Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice. Neoplasma 42: 69-74, 1995.
    • (1995) Neoplasma , vol.42 , pp. 69-74
    • Feleszko, W.1    Lasek, W.2    Golab, J.3    Jakobisiak, M.4
  • 44
    • 33846273797 scopus 로고    scopus 로고
    • Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: The PIOSTAT study
    • Hanefeld M, Marx N, Pfutzner A, et al: Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT study. J Am Coll Cardiol 49: 290-297, 2007.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 290-297
    • Hanefeld, M.1    Marx, N.2    Pfutzner, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.